Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Downregulation of MED12 via siRNA in SPHEROIDS derived from prostate cancer cell lines (3’ tag DGE)

ABSTRACT: Downregulation of MED12 via siRNA in SPHEROIDS derived from prostate cancer cell lines (3’ tag DGE)

PROVIDER: PRJNA1120054 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR29285337.fastq.gz	Fastqsanger.gz
	SRR29285338.fastq.gz	Fastqsanger.gz
	SRR29285339.fastq.gz	Fastqsanger.gz
	SRR29285340.fastq.gz	Fastqsanger.gz
	SRR29285341.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 16

Similar Datasets

Downregulation of MED12 via siRNA in prostate cancer cell lines (3’ tag DGE)

Project description:Downregulation of MED12 via siRNA in prostate cancer cell lines (3’ tag DGE)

| PRJNA1120050 | ENA

Downregulation of MED12 via siRNA in SPHEROIDS derived from prostate cancer cell lines (3’ tag DGE)

Project description:The Mediator complex is a multi-subunit protein that modulates gene expression on a genome-wide scale. MED12 and cyclin-dependent kinase 8 (CDK8) or its paralog CDK19 are components of its kinase module that regulate the proliferation of prostate cancer cells. In this study, we investigated how MED12 and CDK8/19 influence cancer-driven processes in prostate cancer cell lines, focusing on AR activity and enzalutamide resistance.

2024-09-26 | GSE269073 | GEO

Downregulation of MED12 via siRNA in prostate cancer cell lines (3’ tag DGE)

2024-09-26 | GSE269072 | GEO

Downregulation of MED12 via siRNA in 22Rv1 prostate cancer cells (full transcriptome)

Project description:Downregulation of MED12 via siRNA in 22Rv1 prostate cancer cells (full transcriptome)

| PRJNA1120052 | ENA

Downregulation of MED12 via siRNA in 22Rv1 prostate cancer cells (full transcriptome)

2024-09-26 | GSE269070 | GEO

human hTERT-RPE1 cell spheroid : Control siRNA transfected vs. YAP1 siRNA transfected

Project description:Transcriptional profiling of human hTERT-RPE1 cell spheroids comparing Control siRNA transfected hTERT-RPE1 cell spheroids with those transfected with YAP1 siRNA.

2015-02-01 | GSE54146 | GEO

human hTERT-RPE1 cell spheroid : Control siRNA transfected vs. YAP1 siRNA transfected

Project description:Transcriptional profiling of human hTERT-RPE1 cell spheroids comparing Control siRNA transfected hTERT-RPE1 cell spheroids with those transfected with YAP1 siRNA. Two-condition experiment, Control siRNA vs.YAP1 siRNA hTERT-RPE1 cell spheroids. Biological replicates: 1 Control siRNA, 1YAP1 siRNA transfected, independently grown and harvested. Bothreplicates per array.

2015-02-01 | E-GEOD-54146 | biostudies-arrayexpress

Determination of MED12 protein interactome

Project description:Here, the goal of our study was to determine the protein-protein interactome of MED12 in resting and activated human T-cells. We immunoprecipitated endogenous MED12 and evaluated the protein interactome in comparison to an isotype-matched IgG as a control.

2024-12-05 | PXD056255 | Pride

Maternal Med12 safeguards trophoblast pluripotency and placental development

Project description:For a brief but critical period post-fertilization, the mammalian embryo is entirely dependent on maternal products inherited from the oocyte. Previous research showed that oocyte-specific loss of Med12, an X-linked gene and Mediator complex subunit, leads to female sterility despite normal folliculogenesis and ovulation. Here, we show that loss of maternal Med12 has minimal effect on the oocyte transcriptome and does not manifest in embryonic lethality until post-implantation. Implants derived from Med12-null oocytes demonstrate abnormal placentation at E9.5, with an overabundance of trophoblast giant cells (TGC). This phenotype associates with downregulation of trophoblast pluripotency markers (e.g. Cdx2) and activation of drivers of TGC identity (e.g. Stra13) in the E7.5 extraembryonic ectoderm, revealing a previously undescribed role for Med12 in trophoblast pluripotency maintenance. Notably, we find consistently low Med12 expression in embryos derived from Med12-null oocytes, potentially due to programmed paternal X chromosome inactivation (XCI). To isolate the consequences of maternal Med12 depletion, we introduced an autosomal Med12 transgene and show that embryonic expression of the transgene rescues development of Med12-null oocytes. We conclude that oocyte-specific deletion of Med12 produces a maternal-zygotic double knock-out in extraembryonic tissues due to paternal XCI, leading to loss of pluripotency in the trophoblast, placental malformation, and embryonic death.

2025-05-13 | GSE281910 | GEO

Gene expression data in A172 cell line transfected with MED12 siRNA or its control

Project description:This study identifies the genes differentially expressed upon MED12 knockdown in A172 glioblastoma cell line. Clariom_S_Human Array was used to assess mRNA expression profile in response to MED12 Knockdown in A172 cells.

2022-01-01 | GSE176187 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data